#ASH18: Blue­bird and Cel­gene didn’t 'break' their next-gen BC­MA CAR-T, so now they’ll dou­ble down on the dose and root for re­al dura­bil­i­ty

Af­ter the lat­est round of da­ta on bb2121 from blue­bird and Cel­gene left some of the more, um, de­mand­ing an­a­lysts dis­ap­point­ed in terms of dura­bil­i­ty, the ante has been raised sub­stan­tial­ly on the bet they’re mak­ing on their sec­ond-gen CAR-T — bb21217.

De­signed to re­ly more on mem­o­ry cells to amp up the ef­fi­ca­cy — a per­fect­ly rea­son­able the­o­ry that re­lies heav­i­ly on mouse da­ta for its proof-of-con­cept ra­tio­nale — bb21217 de­buted its first da­ta snap­shot at ASH on Sun­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER